buyModerate

Lynx1 Capital Management LP bought $3.3M of NEUP

owner at Neuphoria Therapeutics Inc.. 639,110 shares at an average of $5.14, traded Oct 21, 2025, filed Oct 23, 2025.

Conviction score

Value

$3.3M

639,110 shares

Holdings after

875,328

+271% from before

From 52-week low

no price yet

From 52-week high

no price yet

Score components

Role
10% owner
+12
Trade size
$3.3M at market
+25
Relative to holdings
Holdings up 271%
+10
Price context
No price history yet
0
Cluster
No other insider buying within 14 days
0
Repeat buying
First buy in 90 days
0
Track record
Too few past buys to judge (1 with prices)
0
Outside holder
A 10% owner who is not an officer or director
-5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +10.1%, 3m +3.0%, 6m +21.2%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

NEUPOct 13, 2026 · close 3.39

Since filing Oct 23, 2025: -16.3%SPY +17.1% · excess -33.4%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000902664-25-004536, as filed. Open on EDGAR

Date	Transaction	Shares	Price	Value	Holdings after	Filed
Oct 21, 2025	POpen-market purchase Common stock, $0.00001 par value per shareindirect: See footnote	+639,110	$5.14	$3.3M	875,328	Oct 23, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.